During the past decade, Rex Cancer Center of Wakefield conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 10 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rex Cancer Center of Wakefield" #1 sponsor was "National Cancer Institute (NCI)" with 6 trials, followed by "Alliance for Clinical Trials in Oncology" with 5 trials sponsored, "SWOG Cancer Research Network" with 4 trials sponsored, "Pfizer" with 3 trials sponsored and "NRG Oncology" with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rex Cancer Center of Wakefield" #1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Rex Cancer Center of Wakefield" are "Colorectal Cancer" (5 trials), "Breast Cancer" (3 trials), "Invasive Breast Carcinoma" (3 trials), "Anatomic Stage II Breast Cancer AJCC v8" (2 trials) and "Anatomic Stage IIA Breast Cancer AJCC v8" (2 trials). Many other conditions were trialed in "Rex Cancer Center of Wakefield" in a lesser frequency.

Most popular intervention types in "Rex Cancer Center of Wakefield" are "Drug" (25 trials), "Other" (13 trials), "Biological" (7 trials), "Procedure" (6 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Paclitaxel" (4 trials), "Quality-of-Life Assessment" (4 trials), "oxaliplatin" (4 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Rex Cancer Center of Wakefield" are 25 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Rex Cancer Center of Wakefield". undefined are not yet recruiting, 6 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Rex Cancer Center of Wakefield, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Rex Cancer Center of Wakefield, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".